About Us
Our group applies principles of biomaterials science, tissue engineering and nanotechnology towards translational immunotherapies for cancer, allergy, infectious disease, and autoimmunity. We employ polymeric nanoparticles to deliver life-saving drugs to diseased tissue while sparing healthy tissue from toxicity. Our goal is to modulate the immune system in a controlled manner to address some of the biggest challenges in human health.Latest in the Lab
-
A biomimetic multi-component subunit vaccine via ratiometric loading of hierarchical hydrogels
-
Dual Treatment of Chronic Chagasic Cardiomyopathy and Parasitic Burden via Combination Nanotherapy
-
Pinocytosis inhibitory nanoparticles enhance aPD-1 antibody delivery and efficacy while avoiding toxicity in the treatment of solid tumors
Principal Investigator
Evan Scott, Ph.D.
Thomas A. Saunders III Family Jefferson Scholars Foundation Distinguished University Professor, Biomedical Engineering
Evan Scott, renowned for his groundbreaking work in nanotechnology to address cancer, glaucoma, heart disease, and other conditions, leads the Institute for Nanoscale Scientific and Technological Advanced Research (nanoSTAR) and brings considerable experience to the BME in areas of biomaterials science, nanotechnology, and tissue engineering.